Quick Answer
Armata Pharmaceuticals, Inc. reported Operating Income Loss of -$36.63 million for the year ending 2025.
- Armata Pharmaceuticals, Inc. showed an increase of +13.7% in Operating Income Loss from 2024 to 2025.
- This data is from Armata Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Armata Pharmaceuticals, Inc.'s Operating Income Loss has declined by 195.8%.
- Historical annual values: Fiscal year 2025: -$36.63 million | Fiscal year 2024: -$42.44 million | Fiscal year 2023: -$40.89 million | Fiscal year 2022: -$36.95 million | Fiscal year 2021: -$23.82 million | Fiscal year 2020: -$21.59 million | Fiscal year 2019: -$19.75 million | Fiscal year 2018: -$17.66 million | Fiscal year 2017: -$16.16 million | Fiscal year 2016: -$23.38 million | Fiscal year 2015: -$10.23 million | Fiscal year 2014: -$14.11 million | Fiscal year 2013: -$12.38 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: